Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Wolter

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Personalized Medicine|June 27, 2024
Digenic Inheritance of Mutations in Homologous Recombination Genes in Cancer PatientsMaria Valeria Freire, Marie Martin, Karin Segers, et al.
Haematologica|November 8, 2011
t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34Mathijs Baens, Julio Finalet Ferreiro, Thomas Tousseyn, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
The Journal of Urology|December 5, 2012
A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistanceJoost Berkers, Olivier Govaere, Pascal Wolter, et al.
Radiology. Imaging Cancer|April 5, 2021
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of OutcomeKatja N De Paepe, Ciska-Anne Van Keerberghen, Giorgio M Agazzi, et al.
Oncotarget|April 15, 2015
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohortJérémie Nsengimana, Jon Laye, Anastasia Filia, et al.
Acta Clinica Belgica|May 25, 2018
ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinibEmilie Werbrouck, Julie Bastin, Diether Lambrechts, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
International Journal of Cancer|November 18, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanomaRainer Tuominen, Rosalyn Jewell, Joost J van den Oord, et al.
Acta Clinica Belgica|May 19, 2018
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapiesJulie Bastin, Emilie Werbrouck, Annelies Verbiest, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Personalized Medicine|June 27, 2024
Digenic Inheritance of Mutations in Homologous Recombination Genes in Cancer PatientsMaria Valeria Freire, Marie Martin, Karin Segers, et al.
Haematologica|November 8, 2011
t(X;14)(p11.4;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34Mathijs Baens, Julio Finalet Ferreiro, Thomas Tousseyn, et al.
Melanoma Research|May 12, 2018
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel studyPaolo A Ascierto, Lars Bastholt, Pier F Ferrucci, et al.
The Journal of Urology|December 5, 2012
A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistanceJoost Berkers, Olivier Govaere, Pascal Wolter, et al.
Radiology. Imaging Cancer|April 5, 2021
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of OutcomeKatja N De Paepe, Ciska-Anne Van Keerberghen, Giorgio M Agazzi, et al.
Oncotarget|April 15, 2015
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohortJérémie Nsengimana, Jon Laye, Anastasia Filia, et al.
Acta Clinica Belgica|May 25, 2018
ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinibEmilie Werbrouck, Julie Bastin, Diether Lambrechts, et al.
Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.
International Journal of Cancer|November 18, 2014
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanomaRainer Tuominen, Rosalyn Jewell, Joost J van den Oord, et al.
Acta Clinica Belgica|May 19, 2018
Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapiesJulie Bastin, Emilie Werbrouck, Annelies Verbiest, et al.
Pageof 6